Cognition Therapeutics (NASDAQ:CGTX) Given Buy Rating at Chardan Capital

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reiterated by Chardan Capital in a report issued on Friday,Benzinga reports. They currently have a $11.00 target price on the stock.

Several other research firms also recently weighed in on CGTX. B. Riley restated a “neutral” rating and issued a $1.00 price target (down from $5.00) on shares of Cognition Therapeutics in a research note on Tuesday, August 6th. Cantor Fitzgerald lowered shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, July 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Cognition Therapeutics in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Cognition Therapeutics Stock Down 9.9 %

NASDAQ:CGTX traded down $0.05 during trading hours on Friday, hitting $0.46. 332,087 shares of the stock traded hands, compared to its average volume of 493,689. The stock has a 50 day moving average price of $0.50 and a 200 day moving average price of $1.22. The company has a market cap of $18.51 million, a price-to-earnings ratio of -0.48 and a beta of 1.34. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95.

Hedge Funds Weigh In On Cognition Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CGTX. Tocqueville Asset Management L.P. bought a new position in Cognition Therapeutics in the 1st quarter worth about $47,000. Levin Capital Strategies L.P. purchased a new position in shares of Cognition Therapeutics in the 1st quarter worth approximately $55,000. Bangor Savings Bank raised its stake in shares of Cognition Therapeutics by 41.6% during the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. Sigma Planning Corp boosted its stake in Cognition Therapeutics by 14.6% in the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after acquiring an additional 25,050 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its holdings in Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the last quarter. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.